CSIMarket Company Name, Ticker, Suppliers, else..
 
Mediwound Ltd   (NASDAQ: MDWD)
Other Ticker:  
 
 
Price: $17.1500 $0.02 0.117%
Day's High: $17.68 Week Perf: -5.09 %
Day's Low: $ 16.80 30 Day Perf: -3.81 %
Volume (M): 73 52 Wk High: $ 24.00
Volume (M$): $ 1,246 52 Wk Avg: $16.11
Open: $17.16 52 Wk Low: $9.93



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 34
 Capital Exp. (TTM) (Millions $) 6

Mediwound Ltd
MediWound Ltd is a biopharmaceutical company that specializes in developing and commercializing novel products for the treatment of severe burns and chronic wounds. Their flagship product, NexoBrid, is an enzymatic debridement agent that significantly reduces the need for surgical intervention in burn patients. It works by selectively removing dead tissues, allowing for faster healing and reduced scarring. MediWound also offers other wound care products, such as EscharEx for chronic wounds.


   Company Address: 42 Hayarkon Street Yavne 8122745
   Company Phone Number: 971-4100   Stock Exchange / Ticker: NASDAQ MDWD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BCDA      0% 
BEAT   -3.82%    
PSTV        0.75% 
UEEC   -9.55%    
• View Complete Report
   



Clinical Study

Evaluating Innovations in Wound Care MediWounds Phase II Study on EscharEx vs. Collagenase for Venous Leg Ulcers

Published Thu, Oct 10 2024 11:00 AM UTC

In a significant advance for the field of wound management, MediWound Ltd has announced the commencement of a Phase II head-to-head study assessing the efficacy of EscharEx, an innovative enzyme-based therapy, against collagenase in the treatment of venous leg ulcers. This head-to-head study not only highlights the urgency of addressing venous leg ulcers, which affect millio...
Clinical Study

In November 2023, MediWound Ltd announced the findings from the Phase II ChronEx study concerning EscharEx,...

Published Mon, Jul 29 2024 12:00 PM UTC

The Evolution of Wound Care: MediWound?s EscharEx Study Results and Their Implications for Venous Leg Ulcer Management In November 2023, MediWound Ltd announced the findings from the Phase II ChronEx study concerning EscharEx, a novel enzymatic debriding agent designed to enhance treatment outcomes for venous leg ulcers (VLUs). The study results, published in The Lancet s eC...
Financing Agreement

MediWound Secures $15 Million Investment from Mlnlycke Health Care, But Quick Ratio Rankings Decline in Q4 2023

Published Mon, Jul 15 2024 11:00 AM UTC


Mlnlycke Health Care, a global leader in innovative wound care solutions, has made a significant investment of $15 million in a private placement financing round. This investment positions Mlnlycke Health Care as the leading participant in the financing, demonstrating its commitment to advancing the field of wound care solutions.
However, despite a decrease in curre...
Stocks on the Move

MediWound Ltd Outperforms Market Despite Recent Acquisition Reports

Published Thu, Jul 11 2024 6:19 AM UTC

In the past week, shares of Mediwound Ltd have shown a slight decline compared to the overall market performance. However, when looking at the bigger picture, the company has outperformed the market over the past 12 months. Recent events surrounding an acquisition bid by Solventum have attracted significant attention and impacted investors perceptions. Additionally, Mediwou...
Clinical Study

Promising EscharEx Phase II Data Amidst Revenue Struggle: A Mediwound Analysis

Published Thu, Apr 25 2024 12:00 PM UTC

In-depth findings generated from the Phase II Studies of EscharEx, a product of MediWound, were recently revealed at three major global wound care conferences. These data have elucidated the comparative potential of EscharEx and SANTYL, showcasing a strong correlation between wound bed preparation and pacing of wound healing. Despite the promising results, the fiscal situati...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com